Literature DB >> 21975329

Or why translational research is vital for the future treatment of rectal cancer.

R Glynne-Jones, M Harrison.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21975329     DOI： 10.1007/s12094-011-0718-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  7 in total

1.  High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Kyubo Kim; Eui Kyu Chie; Hong-Gyun Wu; Sang Gyun Kim; Seung-Hee Lee; Gyeong Hoon Kang; Chang Lim Hyun; Sung W Ha
Journal:  Int J Colorectal Dis       Date:  2011-03-19       Impact factor: 2.571

2.  Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways.

Authors:  Scott T Kelley; Domenico Coppola; Timothy Yeatman; Jorge Marcet
Journal:  Clin Colorectal Cancer       Date:  2005-07       Impact factor: 4.481

3.  Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment.

Authors:  Chris J Hunter; Aurelie Garant; Té Vuong; Giovanni Artho; Robert Lisbona; Paris Tekkis; Muti Abulafi; Gina Brown
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

4.  Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?

Authors:  Karoline Horisberger; Philipp Erben; Philipp Ströbel; Beatrice Bohn; Melanie Hahn; Georg Kähler; Frederik Wenz; Andreas Hochhaus; Stefan Post; Frank Willeke; Ralf-Dieter Hofheinz
Journal:  Onkologie       Date:  2010-07-22

5.  Molecular changes consistent with increased proliferation and invasion are common in rectal cancer.

Authors:  R Hughes; J Parry; J Beynon; G Jenkins
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

6.  Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.

Authors:  Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan Moran; Lennart Blomqvist; Ian Swift; David J Sebag-Montefiore; Paris Tekkis; Gina Brown
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

7.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.